



Presented by the Duke Cancer Network In Collaboration with the Duke Cancer Institute

Navigating Immunotoxicities from Cancer Therapies

March 17, 2023

Location JB Duke Hotel 230 Science Dr. Durham, NC

Registration Register online at https://bit.ly/NavImmuno23

Contact/Questions If you are interested in exhibiting at this conference, please contact Beth Tanner at 919-971-3627 or <u>beth.tanner@duke.edu</u>

Description:

Immunotherapeutic approaches to cancer treatment use a patient's own immune system to target cancer cells. The side effects associated with traditional treatment options such as chemotherapy and radiation make immunotherapeutic options appealing. The immune system can identify cancer cells in one of two ways: by recognizing tumor-specific antigens or mutations, or by recognizing tumor associated antigens. Immunotherapy offers effective treatment options for cancer that offer long-lasting effects with improved overall survival and treatment tolerance. Immunotherapy can also cause organ specific toxicities or immune related adverse events. The recognition of these toxicities and their management is forefront for the clinicians caring for the oncology patient. The Duke Cancer Institute Center for Immunotherapy and the Duke Cancer Network are partnering to utilize a multidisciplinary team of oncology and immunology experts and researchers to educate on immunotoxicities occurring in cancer patients as well as management for these toxicities.

Objectives:

- Identify common immune related adverse events seen from the use of cancer immunotherapeutic agents
- Recognize various immunotoxicities effect on specific organ systems
- Examine organ-specific clinical cases, diagnostic tests and current guidelines used to guide management and treatment of the patient experiencing an immune-related adverse event

Presented by the Duke Cancer Network In Collaboration with the Duke Cancer Institute

Navigating Immunotoxicities from Cancer Therapies

March 17, 2023



Duke Cancer Institute

Agenda

Joint Accreditation Statement



In support of improving patient care, the Duke University Health System Department of Clinical Education and Professional Development is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the health care team.

Credit Statement

Physicians: Duke University Health System Department of Clinical Education and Professional Development designates this live activity for a maximum of 7 A PRA Category 1 Credit(s)[™] . Physicians should clair only credit commensurate with the extent of the participation in the activity.

Nursing: Duke University Health System Department of Clinical Education and Professional Developme designates this activity for up to 7 credit hours for nurses. Nurses should claim only credit commensurate with the extent of their participation in this activity.

Pharmacists: Duke University Health System Department of Clinical Education and Professional Development designates this activity for up to 7 ACPE credit hours. Universal Activity Numbers: JA0000655-0000-23-128-L04-P/T.



Course Directors

Afreen Shariff, MD, MBBS Assistant Professor of Medicine Director, Duke Endo-Oncology Program Associate Director Multi-Disciplinary Toxicity Program DCI Center for Cancer Immunotherapy

Linda Sutton, MD Associate Chief Medical Officer Duke Network Services Professor of Medicine Duke University Health System


Duke Faculty

Coral Giovacchini, MD Assistant Professor of Medicine

Meenal Kheterpal, MD Assistant Professor of Dermatology

Michel Khouri, MD Associate Professor of Medicine

d Ortiz-Melo, MD tant Profe<u>ssor o</u>f Medicine



Michael Dougan, MD, PhD Assistant Professor of Medicine Massachusetts General Hospital Harvard Medical School

Jon McDunn, PhD **Executive Director** Project Data Sphere

Kerry Reynolds, MD Clinical Director, Inpatient Oncology Units Director, Severe Immunotherapy Complications Service Massachussetts General Hospital

Yousuf Zafar, MD Senior Vice President, Medical Informatics Change Healthcare Adjunct Professor of Medicine Duke University School of Medicine

Disclaimer: The information provided at this activity is for continuing medical education purposes only and is not meant to substitute the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.

7:15 a.m. – 7:55 a.m.	Registration/ Breakfast
7:55 a.m. – 8:00 a.m.	Welcome Afreen Shariff, MD, MBBS
8:00 a.m. – 8:50 a.m.	Keynote Address: Immune Mediated Toxicities: The Past, Present and the Future Kerry Reynolds, MD
8:50 a.m. – 9:30 a.m.	Endocrine Adverse Events Afreen Shariff, MD, MBBS
9:30 a.m. – 10:00 a.m.	Renal Adverse Events David Ortiz-Melo, MD
10:00 a.m. – 10:30 a.m.	Break and Exhibitor Showcase
10:30 a.m. – 11:10 a.m.	Gastrointestinal Adverse Events Michael Dougan, MD, PhD
11:10 m 10 a.m	Rheumotologic Adverse Events Sruna Weitmann, MD Eumatologic Adverse Events Augnal Khetovpal, MD
12:10 .m. – 12:55 p.m.	
1:00 p.m. – 1:30 p.m.	Cardiac Adverse Events Michel Khouri, MD
1:30 p.m. – 2:00 p.m.	Neuromuscular Adverse Events Suma Shah, MD
2:00 p.m. – 2:30 p.m.	Break and Exhibitor Showcase
2:40 p.m. – 3:20 p.m.	Pulmonary Adverse Events Coral Giovacchini, MD
3:20 p.m. – 4:30 p.m.	Panel Discussion: Rethinking Toxicity Management Afreen Shariff, MD, MBBS Featuring: Michel Khouri, MD; Jon McDunn, PhD; David Ortiz-Melo, MD; Kerry Reynolds, MD; Yousuf Zafar, MD
4:30 p.m. – 4:35 p.m.	Closing Remarks